Familial Neurohypophyseal Diabetes Insipidus-An Update

Seminars in Nephrology

Volumn 26, Issue 3, 2006, Pages 209-223

  Christensen, Jane H ^a   Rittig, Søren ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

AVP gene; inheritance; mutation; neurohypophyseal diabetes insipidus; pathogenesis

Indexed keywords

ARGIPRESSIN; DESMOPRESSIN; HORMONE PRECURSOR;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BIOSYNTHESIS; CLINICAL FEATURE; DIABETES INSIPIDUS; DIFFERENTIAL DIAGNOSIS; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GIANT CELL; HUMAN; INHERITANCE; NERVE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; QUALITY CONTROL;

ANIMALS; DIABETES INSIPIDUS, NEUROGENIC; HUMANS; MUTATION; NEUROPHYSINS;

EID: 33646497845     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.03.003     Document Type: Article

References (166)

1. Gainer H., Yamashita M., Fields R.L., et al. The magnocellular neuronal phenotype. Cell-specific gene expression in the hypothalamo-neurohypophysial system. Prog Brain Res 139 (2002) 1-14
2. Murphy D., and Wells S. In vivo gene transfer studies on the regulation and function of the vasopressin and oxytocin genes. J Neuroendocrinol 15 (2003) 109-125
3. Mohr E., and Richter D. Subcellular vasopressin mRNA trafficking and local translation in dendrites. J Neuroendocrinol 16 (2004) 333-339
4. Breslow E. Structure and folding properties of neurophysin and its peptide complexes. Biological implications. Regul Pept 45 (1993) 15-19
5. de Bree F.M., and Burbach J.P. Structure-function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol 18 (1998) 173-191
6. de Bree F.M. Trafficking of the vasopressin and oxytocin prohormone through the regulated secretory pathway. J Neuroendocrinol 12 (2000) 589-594
7. Burman S., Wellner D., Chait B., et al. Complete assignment of neurophysin disulfides indicates pairing in two separate domains. Proc Natl Acad Sci U S A 86 (1989) 429-433
8. Ivell R., Schmale H., and Richter D. Glycosylation of the arginine vasopressin/neurophysin II common precursor. Biochem Biophys Res Commun 102 (1981) 1230-1236
9. Eubanks S., Nguyen T.L., Peyton D., et al. Modulation of dimerization, binding, stability, and folding by mutation of the neurophysin subunit interface. Biochemistry 39 (2000) 8085-8094
10. de Bree F.M., Knight D., Howell L., et al. Sorting of the vasopressin prohormone into the regulated secretory pathway. FEBS Lett 475 (2000) 175-180
11. Gainer H., and Chin H. Molecular diversity in neurosecretion. Reflections on the hypothalamo-neurohypophysial system. Cell Mol Neurobiol 18 (1998) 211-230
12. Acher R., Chauvet J., and Rouille Y. Dynamic processing of neuropeptides. Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci 18 (2002) 223-228
13. Ward D.T., Hammond T.G., and Harris H.W. Modulation of vasopressin-elicited water transport by trafficking of aquaporin2-containing vesicles. Annu Rev Physiol 61 (1999) 683-697
14. Fujiwara T.M., and Bichet D.G. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 16 (2005) 2836-2846
15. Christensen J.H., Siggaard C., Corydon T.J., et al. Six novel mutations in the arginine vasopressin gene in 15 kindreds with autosomal dominant familial neurohypophyseal diabetes insipidus give further insight into the pathogenesis. Eur J Hum Genet 12 (2004) 44-51
16. Willcutts M.D., Felner E., and White P.C. Autosomal recessive familial neurohypophyseal diabetes insipidus with continued secretion of mutant weakly active vasopressin. Hum Mol Genet 8 (1999) 1303-1307
17. Forssman H. On hereditary diabetes insipidus with special regard to a sex-linked form. Acta Med Scand 159 suppl (1945) 1-196
18. Robertson G.L., Kopp P., Rittig S., et al. Rediscovery of Swedish kindred with x-linked 'vasopressin-responsive' diabetes insipidus. Validation and explanation of the unusual clinical phenotype (2004). http://www.ndif.org/conf04/pab-Robertson04.html Presented at the Fifth Global Conference of the NDI Foundation, Phoenix, AZ, April 10, (http://www.ndif.org/conf04/pab-Robertson04.html)
19. Hansen L.K., Rittig S., and Robertson G.L. Genetic basis of familial neurohypophyseal diabetes insipidus. Trends Endocrinol Metab 8 (1997) 363-372
20. Habiby R.L., Robertson G.L., Kaplowitz P.B., et al. A novel X-linked form of familial neurohypophyseal diabetes insipidus. J Invest Med 44 (1996) 388A (abstr)
21. Riddell D.C., Mallonee R., Phillips J.A., et al. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somat Cell Mol Genet 11 (1985) 189-195
22. Summar M.L., Phillips J.A., Battey J., et al. Linkage relationships of human arginine vasopressin-neurophysin-II and oxytocin-neurophysin-I to prodynorphin and other loci on chromosome 20. Mol Endocrinol 4 (1990) 947-950
23. Rao V.V., Loffler C., Battey J., et al. The human gene for oxytocin-neurophysin I (OXT) is physically mapped to chromosome 20p13 by in situ hybridization. Cytogenet Cell Genet 61 (1992) 271-273
24. Land H., Schutz G., Schmale H., et al. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 295 (1982) 299-303
25. Sausville E., Carney D., and Battey J. The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. J Biol Chem 260 (1985) 10236-10241
26. Gainer H., Fields R.L., and House S.B. Vasopressin gene expression. Experimental models and strategies. Exp Neurol 171 (2001) 190-199
27. Ivell R., and Richter D. Structure and comparison of the oxytocin and vasopressin genes from rat. Proc Natl Acad Sci U S A 81 (1984) 2006-2010
28. Morello J.P., and Bichet D.G. Nephrogenic diabetes insipidus. Annu Rev Physiol 63 (2001) 607-630
29. Figueroa J., Morley S.D., Heierhorst J., et al. Two isotocin genes are present in the white sucker Catostomus commersoni both lacking introns in their protein coding regions. EMBO J 8 (1989) 2873-2877
30. Heierhorst J., Lederis K., and Richter D. Presence of a member of the Tc1-like transposon family from nematodes and Drosophila within the vasotocin gene of a primitive vertebrate, the Pacific hagfish Eptatretus stouti. Proc Natl Acad Sci U S A 89 (1992) 6798-6802
31. Hyodo S., Ishii S., and Joss J.M. Australian lungfish neurohypophysial hormone genes encode vasotocin and [Phe2]mesotocin precursors homologous to tetrapod-type precursors. Proc Natl Acad Sci U S A 94 (1997) 13339-13344
32. Burbach J.P., Luckman S.M., Murphy D., et al. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 81 (2001) 1197-1267
33. Acher R. Neurohypophysial peptide systems. Processing machinery, hydroosmotic regulation, adaptation and evolution. Regul Pept 45 (1993) 1-13
34. Hoyle C.H. Neuropeptide families. Evolutionary perspectives. Regul Pept 73 (1998) 1-33
35. Acher R. Molecular evolution of biologically active polypeptides. Proc R Soc Lond B Biol Sci 210 (1980) 21-43
36. Glasgow E., Kusano K., Chin H., et al. Single cell reverse transcription-polymerase chain reaction analysis of rat supraoptic magnocellular neurons. Neuropeptide phenotypes and high voltage-gated calcium channel subtypes. Endocrinology 140 (1999) 5391-5401
37. Xi D., Kusano K., and Gainer H. Quantitative analysis of oxytocin and vasopressin messenger ribonucleic acids in single magnocellular neurons isolated from supraoptic nucleus of rat hypothalamus. Endocrinology 140 (1999) 4677-4682
38. Gainer H. Cell-specific gene expression in oxytocin and vasopressin magnocellular neurons. Adv Exp Med Biol 449 (1998) 15-27
39. Fields R.L., House S.B., and Gainer H. Regulatory domains in the intergenic region of the oxytocin and vasopressin genes that control their hypothalamus-specific expression in vitro. J Neurosci 23 (2003) 7801-7809
40. Chen L.Q., Rose J.P., Breslow E., et al. Crystal structure of a bovine neurophysin II dipeptide complex at 2.8 A determined from the single-wavelength anomalous scattering signal of an incorporated iodine atom. Proc Natl Acad Sci U S A 88 (1991) 4240-4244
41. Barat C., Simpson L., and Breslow E. Properties of human vasopressin precursor constructs. Inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry 43 (2004) 8191-8203
42. Sitia R., and Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 426 (2003) 891-894
43. Lee M.C., Miller E.A., Goldberg J., et al. Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol 20 (2004) 87-123
44. Romisch K. Endoplasmic reticulum-associated degradation. Annu Rev Cell Dev Biol 21 (2005) 435-456
45. Arvan P., and Castle D. Sorting and storage during secretory granule biogenesis. Looking backward and looking forward. Biochem J 332 (1998) 593-610
46. Gerdes H.H., Rosa P., Phillips E., et al. The primary structure of human secretogranin II, a widespread tyrosine-sulfated secretory granule protein that exhibits low pH- and calcium-induced aggregation. J Biol Chem 264 (1989) 12009-12015
47. Chanat E., and Huttner W.B. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 115 (1991) 1505-1519
48. Zhang B.J., Yamashita M., Fields R., et al. EGFP-tagged vasopressin precursor protein sorting into large dense core vesicles and secretion from PC12 cells. Cell Mol Neurobiol 25 (2005) 581-605
49. de Bree F.M., Van Der Kleij A.A., Nijenhuis M., et al. The hormone domain of the vasopressin prohormone is required for the correct prohormone trafficking through the secretory pathway. J Neuroendocrinol 15 (2003) 1156-1163
50. Gainer H. Mechanisms of intracellular trafficking and processing of pro-proteins. In: Loh Y.P. (Ed). Intracellular Protein Trafficking and Proprotein Processing. An Overview (1993), CRC Press, Boca Raton, FL 1-17
51. Seidah N.G., Gaspar L., Mion P., et al. cDNA sequence of two distinct pituitary proteins homologous to Kex2 and furin gene products. Tissue-specific mRNAs encoding candidates for pro-hormone processing proteinases. DNA Cell Biol 9 (1990) 415-424
52. Gainer H., Sarne Y., and Brownstein M.J. Neurophysin biosynthesis. Conversion of a putative precursor during axonal transport. Science 195 (1977) 1354-1356
53. Breslow E., and Burman S. Molecular, thermodynamic, and biological aspects of recognition and function in neurophysin-hormone systems. A model system for the analysis of protein-peptide interactions. Adv Enzymol Relat Areas Mol Biol 63 (1990) 1-67
54. Tae H.J., Baek K.H., Shim S.M., et al. A novel splice site mutation of the arginine vasopressin-neurophysin II gene identified in a kindred with autosomal dominant familial neurohypophyseal diabetes insipidus. Mol Genet Metab 86 (2005) 307-313
55. Rittig S., Robertson G.L., Siggaard C., et al. Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Am J Hum Genet 58 (1996) 107-117
56. Ye L., Li X., Chen Y., et al. Autosomal dominant neurohypophyseal diabetes insipidus with linkage to chromosome 20p13 but without mutations in the AVP-NPII Gene. J Clin Endocrinol Metab 90 (2005) 4388-4393
57. Abbes A.P., Bruggeman B., van den Akker E.L., et al. Identification of two distinct mutations at the same nucleotide position, concomitantly with a novel polymorphism in the vasopressin-neurophysin II gene (AVP-NP II) in two Dutch families with familial neurohypophyseal diabetes insipidus. Clin Chem 46 (2000) 1699-1702
58. Robertson G.L., Rittig S., Gu W.X., et al. Pathogenesis and pathophysiology of familial neurohypophyseal diabetes insipidus. In: Saito T., Kurokawa K., and Yoshida S. (Eds). Neurohypophysis. Recent Progress of Vasopressin and Oxytocin Research (1995), Elsevier Science B.V, Amsterdam 593-603
59. Ito M., and Jameson J.L. Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. J Clin Invest 99 (1997) 1897-1905
60. Ito M., Yu R.N., and Jameson J.L. Mutant vasopressin precursors that cause autosomal dominant neurohypophyseal diabetes insipidus retain dimerization and impair the secretion of wild-type proteins. J Biol Chem 274 (1999) 9029-9037
61. Davies J., and Murphy D. Autophagy in hypothalamic neurones of rats expressing a familial neurohypophysial diabetes insipidus transgene. J Neuroendocrinol 14 (2002) 629-637
62. Breslow E., and Walter R. Binding properties of bovine neurophysins I and II. An equilibrium dialysis study. Mol Pharmacol 8 (1972) 75-81
63. Ando S., McPhie P., and Chaiken I.M. Sequence redesign and the assembly mechanism of the oxytocin/bovine neurophysin I biosynthetic precursor. J Biol Chem 262 (1987) 12962-12969
64. Deeb R., and Breslow E. Thermodynamic role of the pro region of the neurophysin precursor in neurophysin folding. Evidence from the effects of ligand peptides on folding. Biochemistry 35 (1996) 864-873
65. Breslow E., Mombouyran V., Deeb R., et al. Structural basis of neurophysin hormone specificity. Geometry, polarity, and polarizability in aromatic ring interactions. Protein Sci 8 (1999) 820-831
66. Eubanks S., Lu M., Peyton D., et al. Expression, folding, and thermodynamic properties of the bovine oxytocin-neurophysin precursor. Relationships to the intermolecular oxytocin-neurophysin complex. Biochemistry 38 (1999) 13530-13541
67. Nguyen T.L., and Breslow E. NMR analysis of the monomeric form of a mutant unliganded bovine neurophysin. Comparison with the crystal structure of a neurophysin dimer. Biochemistry 41 (2002) 5920-5930
68. Naik M.T., Lee H., Bracken C., et al. NMR investigation of main-chain dynamics of the H80E mutant of bovine neurophysin-I. Demonstration of dimerization-induced changes at the hormone-binding site. Biochemistry 44 (2005) 11766-11776
69. Rose J.P., Wu C.K., Hsiao C.D., et al. Crystal structure of the neurophysin-oxytocin complex. Nat Struct Biol 3 (1996) 163-169
70. Wu C.K., Hu B., Rose J.P., et al. Structures of an unliganded neurophysin and its vasopressin complex. Implications for binding and allosteric mechanisms. Protein Sci 10 (2001) 1869-1880
71. Huang H.B., and Breslow E. Identification of the unstable neurophysin disulfide and localization to the hormone-binding site. Relationship to folding-unfolding pathways. J Biol Chem 267 (1992) 6750-6756
72. Kanmera T., and Chaiken I.M. Molecular properties of the oxytocin/bovine neurophysin biosynthetic precursor. Studies using a semisynthetic precursor. J Biol Chem 260 (1985) 8474-8482
73. Fassina G., and Chaiken I.M. Structural requirements of peptide hormone binding for peptide-potentiated self-association of bovine neurophysin II. J Biol Chem 263 (1988) 13539-13543
74. Nicolas P., Wolff J., Camier M., et al. Importance of neurophysin dimer and of tyrosine-49 in the binding of neurohypophyseal peptides. J Biol Chem 253 (1978) 2633-2639
75. Eubanks S., Nguyen T.L., Deeb R., et al. Effects of diabetes insipidus mutations on neurophysin folding and function. J Biol Chem 276 (2001) 29671-29680
76. Hanhart E. Die erbpathologie des diabetes insipidus. in Handbuch der Erbbiologie des Menschen (1940), Julius Springer, Berlin 798-823
77. Gaupp R. Über den diabetes insipidus. Z ges Neurol Psychiat 171 (1941) 514-546
78. Green J.R., Buchan G.C., Alvord E.C.J., et al. Hereditary and idiopathic types of diabetes insipidus. Brain 90 (1967) 707-714
79. Braverman L.E., Mancini J.P., and McGoldrick D.M. Hereditary idiopathic diabetes insipidus. A case report with autopsy findings. Ann Intern Med 63 (1965) 503-508
80. Bergeron C., Kovacs K., Ezrin C., et al. Hereditary diabetes insipidus. An immunohistochemical study of the hypothalamus and pituitary gland. Acta Neuropathol 81 (1991) 345-348
81. McLeod J.F., Kovacs L., Gaskill M.B., et al. Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation. J Clin Endocrinol Metab 77 (1993) 599A-599G
82. Friberg M.A., Spiess M., and Rutishauser J. Degradation of wild-type vasopressin precursor and pathogenic mutants by the proteasome. J Biol Chem 279 (2004) 19441-19447
83. Siggaard C., Christensen J.H., Corydon T.J., et al. Expression of three different mutations in the arginine vasopressin gene suggests genotype-phenotype correlation in familial neurohypophyseal diabetes insipidus kindreds. Clin Endocrinol (Oxf) 63 (2005) 207-216
84. Miyamoto S., Sasaki N., and Tanabe Y. Magnetic resonance imaging in familial central diabetes insipidus. Neuroradiology 33 (1991) 272-273
85. Kubota T., Yamamoto T., Ozono K., et al. Hyperintensity of posterior pituitary on MR T1WI in a boy with central diabetes insipidus caused by missense mutation of neurophysin II gene. Endocr J 48 (2001) 459-463
86. Mahoney C.P., Weinberger E., Bryant C., et al. Effects of aging on vasopressin production in a kindred with autosomal dominant neurohypophyseal diabetes insipidus due to the DeltaE47 neurophysin mutation. J Clin Endocrinol Metab 87 (2002) 870-876
87. Olias G., Richter D., and Schmale H. Heterologous expression of human vasopressin-neurophysin precursors in a pituitary cell line. Defective transport of a mutant protein from patients with familial diabetes insipidus. DNA Cell Biol 15 (1996) 929-935
88. Beuret N., Rutishauser J., Bider M.D., et al. Mechanism of endoplasmic reticulum retention of mutant vasopressin precursor caused by a signal peptide truncation associated with diabetes insipidus. J Biol Chem 274 (1999) 18965-18972
89. Siggaard C., Rittig S., Corydon T.J., et al. Clinical and molecular evidence of abnormal processing and trafficking of the vasopressin preprohormone in a large kindred with familial neurohypophyseal diabetes insipidus due to a signal peptide mutation. J Clin Endocrinol Metab 84 (1999) 2933-2941
90. Nijenhuis M., Zalm R., and Burbach J.P. Mutations in the vasopressin prohormone involved in diabetes insipidus impair endoplasmic reticulum export but not sorting. J Biol Chem 274 (1999) 21200-21208
91. Nijenhuis M., Zalm R., and Burbach J.P. A diabetes insipidus vasopressin prohormone altered outside the central core of neurophysin accumulates in the endoplasmic reticulum. Mol Cell Endocrinol 167 (2000) 55-67
92. Nijenhuis M., van den Akker E.L., Zalm R., et al. Familial neurohypophysial diabetes insipidus in a large Dutch kindred. Effect of the onset of diabetes on growth in children and cell biological defects of the mutant vasopressin prohormone. J Clin Endocrinol Metab 86 (2001) 3410-3420
93. Christensen J.H., Siggaard C., Corydon T.J., et al. Impaired trafficking of mutated AVP prohormone in cells expressing rare disease genes causing autosomal dominant familial neurohypophyseal diabetes insipidus. Clin Endocrinol (Oxf) 60 (2004) 125-136
94. Christensen J.H., Siggaard C., Corydon T.J., et al. Differential cellular handling of defective arginine vasopressin (AVP) prohormones in cells expressing mutations of the AVP gene associated with autosomal dominant and recessive familial neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 89 (2004) 4521-4531
95. Russell T.A., Ito M., Ito M., et al. A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest 112 (2003) 1697-1706
96. Si-Hoe S., de Bree F.M., Nijenhuis M., et al. Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophyseal diabetes insipidus mutant vasopressin transgene. FASEB J 14 (2000) 1680-1684
97. Castino R., Davies J., Beaucourt S., et al. Autophagy is a prosurvival mechanism in cells expressing an autosomal dominant familial neurohypophyseal diabetes insipidus mutant vasopressin transgene. FASEB J 19 (2005) 1021-1023
98. Castino R., Isidoro C., and Murphy D. Autophagy-dependent cell survival and cell death in an autosomal dominant familial neurohypophyseal diabetes insipidus in vitro model. FASEB J 19 (2005) 1024-1026
99. Callea F., Brisigotti M., Fabbretti G., et al. Hepatic endoplasmic reticulum storage diseases. Liver 12 (1992) 357-362
100. Kim P.S., and Arvan P. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases. Disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev 19 (1998) 173-202
101. Medeiros-Neto G., Kim P.S., Yoo S.E., et al. Congenital hypothyroid goiter with deficient thyroglobulin. Identification of an endoplasmic reticulum storage disease with induction of molecular chaperones. J Clin Invest 98 (1996) 2838-2844
102. Lamande S.R., Chessler S.D., Golub S.B., et al. Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro alpha 1 (I) chain carboxyl-terminal propeptide which impair subunit assembly. J Biol Chem 270 (1995) 8642-8649
103. Lehrman M.A., Schneider W.J., Brown M.S., et al. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem 262 (1987) 401-410
104. Jensen H.K., Holst H., Jensen L.G., et al. A common W556S mutation in the LDL receptor gene of Danish patients with familial hypercholesterolemia encodes a transport-defective protein. Atherosclerosis 131 (1997) 67-72
105. Jorgensen M.M., Jensen O.N., Holst H.U., et al. Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum. J Biol Chem 275 (2000) 33861-33868
106. Rittig S., Siggaard C., Ozata M., et al. Autosomal dominant neurohypophyseal diabetes insipidus due to substitution of histidine for tyrosine(2) in the vasopressin moiety of the hormone precursor. J Clin Endocrinol Metab 87 (2002) 3351-3355
107. Wahlstrom J.T., Fowler M.J., Nicholson W.E., et al. A novel mutation in the preprovasopressin gene identified in a kindred with autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 89 (2004) 1963-1968
108. Blumenstein M., and Hruby V.J. Interactions of oxytocin with bovine neurophysins I and II. Use of 13C nuclear magnetic resonance and hormones specifically enriched with 13C in the glycinamide-9 and half-cystine-1 positions. Biochemistry 16 (1977) 5169-5177
109. Lacombe U. De la polydipsie. L'experiance. J Med Chir 7 (1841) 323-339
110. Weil A. Ueber die hereditaere Form des Diabetes insipidus. Virchows Arch Path Anat 95 (1884) 70-95
111. McIlraith C.H. Notes on some cases of diabetes insipidus with marked family and hereditary tendencies. Lancet ii (1892) 767-768
112. Elias P.C., Elias L.L., Torres N., et al. Progressive decline of vasopressin secretion in familial autosomal dominant neurohypophyseal diabetes insipidus presenting a novel mutation in the vasopressin-neurophysin II gene. Clin Endocrinol (Oxf) 59 (2003) 511-518
113. Rutishauser J., Boni-Schnetzler M., Boni J., et al. A novel point mutation in the translation initiation codon of the pre- pro-vasopressin-neurophysin II gene. cosegregation with morphological abnormalities and clinical symptoms in autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 81 (1996) 192-198
114. Heppner C., Kotzka J., Bullmann C., et al. Identification of mutations of the arginine vasopressin-neurophysin II gene in two kindreds with familial central diabetes insipidus. J Clin Endocrinol Metab 83 (1998) 693-696
115. Repaske D.R., Medlej R., Gultekin E.K., et al. Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1- ->Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab 82 (1997) 51-56
116. Durr J.A. Diabetes insipidus in pregnancy. Am J Kidney Dis 9 (1987) 276-283
117. Robertson G.L. Differential diagnosis of polyuria. Annu Rev Med 39 (1988) 425-442
118. Tajima T., Nakae J., Takekoshi Y., et al. Three novel AVPR2 mutations in three Japanese families with X-linked nephrogenic diabetes insipidus. Pediatr Res 39 (1996) 522-526
119. Sadeghi H., Robertson G.L., Bichet D.G., et al. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes. Mol Endocrinol 11 (1997) 1806-1813
120. Vargas-Poussou R., Forestier L., Dautzenberg M.D., et al. Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12 families with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 8 (1997) 1855-1862
121. Pasel K., Schulz A., Timmermann K., et al. Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families. J Clin Endocrinol Metab 85 (2000) 1703-1710
122. Inaba S., Hatakeyama H., Taniguchi N., et al. The property of a novel v2 receptor mutant in a patient with nephrogenic diabetes insipidus. J Clin Endocrinol Metab 86 (2001) 381-385
123. Rittig S., Faerch M., Christensen J.H., et al. Clinical phenotype and molecular characterization of a mutant V2 receptor associated with partial congenital nephrogenic diabetes insipidus (2004). http://www.ndif.org/conf04/pab-Rittig04.html Presented at the Fifth Global Conference of the NDI Foundation, Phoenix, AZ, April 10, (http://www.ndif.org/conf04/pab-Rittig04.html)
124. Mizuno H., Sugiyama Y., Ohro Y., et al. Clinical characteristics of eight patients with congenital nephrogenic diabetes insipidus. Endocrine 24 (2004) 55-59
125. Bruins J., Kovacs G.L., Abbes A.P., et al. Minor disturbances in central nervous system function in familial neurohypophysial diabetes insipidus. Psychoneuroendocrinology 31 (2006) 80-91
126. Ghirardello S., Malattia C., Scagnelli P., et al. Current perspective on the pathogenesis of central diabetes insipidus. J Pediatr Endocrinol Metab 18 (2005) 631-645
127. Rutishauser J., Kopp P., Gaskill M.B., et al. Clinical and molecular analysis of three families with autosomal dominant neurohypophyseal diabetes insipidus associated with a novel and recurrent mutations in the vasopressin-neurophysin II gene. Eur J Endocrinol 146 (2002) 649-656
128. Fukuda I., Hizuka N., and Takano K. Oral DDAVP is a good alternative therapy for patients with central diabetes insipidus. Experience of five-year treatment. Endocr J 50 (2003) 437-443
129. Rittig S., Jensen A.R., Jensen K.T., et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 48 (1998) 235-241
130. Bogaert G., Vande Walle J., Mattson S., et al. A pharmacodynamic study in children with primary nocturnal enuresis using a new "melt" orodispersible formulation of desmopressin. Neurourol Urodyn 24 (2005) 578-579 (abstr)
131. Geddes B.J., Harding T.C., Lightman S.L., et al. Long-term gene therapy in the CNS. Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nat Med 3 (1997) 1402-1404
132. Ideno J., Mizukami H., Honda K., et al. Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in brattleboro rats. Mol Ther 8 (2003) 895-902
133. Bienemann A.S., Martin-Rendon E., Cosgrave A.S., et al. Long-term replacement of a mutated nonfunctional CNS gene. Reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Mol Ther 7 (2003) 588-596
134. Yoshida M., Iwasaki Y., Asai M., et al. Gene therapy for central diabetes insipidus. Effective antidiuresis by muscle-targeted gene transfer. Endocrinology 145 (2004) 261-268
135. Schwarz E.R., and Sanghi P. Conivaptan. A selective vasopressin antagonist for the treatment of heart failure. Expert Rev Cardiovasc Ther 4 (2006) 17-23
136. Ito M., Oiso Y., Murase T., et al. Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause for familial central diabetes insipidus. J Clin Invest 91 (1993) 2565-2571
137. Rittig S., Kovacs L., Gregersen N., et al. Familial neurogenic diabetes insipidus in 5 Danish kindreds. In: Gross P., Richter D., and Robertson G.L. (Eds). Vasopressin (1993), John Libbey Eurotext, Paris 600
138. Repaske D.R., Summar M.L., Krishnamani M.R., et al. Recurrent mutations in the vasopressin-neurophysin II gene cause autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 81 (1996) 2328-2334
139. Calvo B., Bilbao J.R., Urrutia I., et al. Identification of a novel nonsense mutation and a missense substitution in the vasopressin-neurophysin II gene in two Spanish kindreds with familial neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 83 (1998) 995-997
140. Boson W.L., Sarubi J.C., D'Alva C.B., et al. A signal peptide mutation of the arginine vasopressin gene in monozygotic twins. Clin Endocrinol (Oxf) 58 (2003) 108-110
141. Kanemitsu N., Kawauchi A., Nishida M., et al. Familial central diabetes insipidus detected by nocturnal enuresis. Pediatr Nephrol 17 (2002) 1063-1065
142. Bahnsen U., Oosting P., Swaab D.F., et al. A missense mutation in the vasopressin-neurophysin precursor gene cosegregates with human autosomal dominant neurohypophyseal diabetes insipidus. EMBO J 11 (1992) 19-23
143. Goking N.Q., Chertow B.S., Robertson G.L., et al. A novel AVP-neurophysin gene mutation in familial neurohypophyseal diabetes insipidus presenting with nocturnal enuresis. J Endocrine Genetics 2 (2001) 105-113
144. Calvo B., Bilbao J.R., Rodriguez A., et al. Molecular analysis in familial neurohypophyseal diabetes insipidus. Early diagnosis of an asymptomatic carrier. J Clin Endocrinol Metab 84 (1999) 3351-3354
145. Gagliardi P.C., Bernasconi S., and Repaske D.R. Autosomal dominant neurohypophyseal diabetes insipidus associated with a missense mutation encoding Gly23->Val in neurophysin II. J Clin Endocrinol Metab 82 (1997) 3643-3646
146. Repaske D.R., and Browning J.E. A de novo mutation in the coding sequence for neurophysin-II (Pro24- >Leu) is associated with onset and transmission of autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 79 (1994) 421-427
147. Wolf M.T., Dotsch J., Metzler M., et al. A new missense mutation of the vasopressin-neurophysin II gene in a family with neurohypophyseal diabetes insipidus. Horm Res 60 (2003) 143-147
148. Skordis N., Patsalis P.C., Hettinger J.A., et al. A novel arginine vasopressin-neurophysin II mutation causes autosomal dominant neurohypophyseal diabetes insipidus and morphologic pituitary changes. Horm Res 53 (2000) 239-245
149. Fluck C.E., Deladoey J., Nayak S., et al. Autosomal dominant neurohypophyseal diabetes insipidus in a Swiss family, caused by a novel mutation (C59Delta/A60W) in the neurophysin moiety of prepro-vasopressin-neurophysin II (AVP-NP II). Eur J Endocrinol 145 (2001) 439-444
150. Yuasa H., Ito M., Nagasaki H., et al. Glu-47, which forms a salt bridge between neurophysin-II and arginine vasopressin, is deleted in patients with familial central diabetes insipidus. J Clin Endocrinol Metab 77 (1993) 600-604
151. Miyakoshi M., Kamoi K., Murase T., et al. Novel mutant vasopressin-neurophysin II gene associated with familial neurohypophyseal diabetes insipidus. Endocr J 51 (2004) 551-556
152. Grant F.D., Ahmadi A., Hosley C.M., et al. Two novel mutations of the vasopressin gene associated with familial diabetes insipidus and identification of an asymptomatic carrier infant. J Clin Endocrinol Metab 83 (1998) 3958-3964
153. Ito M., Mori Y., Oiso Y., et al. A single base substitution in the coding region for neurophysin II associated with familial central diabetes insipidus. J Clin Invest 87 (1991) 725-728
154. Bullmann C., Kotzka J., Grimm T., et al. Identification of a novel mutation in the arginine vasopressin-neurophysin II gene in familial central diabetes insipidus. Exp Clin Endocrinol Diabetes 110 (2002) 134-137
155. Nagasaki H., Ito M., Yuasa H., et al. Two novel mutations in the coding region for neurophysin-II associated with familial central diabetes insipidus. J Clin Endocrinol Metab 80 (1995) 1352-1356
156. Rauch F., Lenzner C., Nurnberg P., et al. A novel mutation in the coding region for neurophysin-II is associated with autosomal dominant neurohypophyseal diabetes insipidus. Clin Endocrinol (Oxf) 44 (1996) 45-51
157. Ueta Y., Taniguchi S., Yoshida A., et al. A new type of familial central diabetes insipidus caused by a single base substitution in the neurophysin II coding region of the vasopressin gene. J Clin Endocrinol Metab 81 (1996) 1787-1790
158. Rutishauser J., Kopp P., Gaskill M.B., et al. A novel mutation (R97C) in the neurophysin moiety of prepro-vasopressin-neurophysin II associated with autosomal-dominant neurohypophyseal diabetes insipidus. Mol Genet Metab 67 (1999) 89-92
159. Mundschenk J., Rittig S., Siggaard C., et al. A new mutation of the arginine vasopressin-neurophysin II gene in a family with autosomal dominant neurohypophyseal diabetes insipidus. Exp Clin Endocrinol Diabetes 109 (2001) 406-409
160. DiMeglio L.A., Gagliardi P.C., Browning J.E., et al. A missense mutation encoding cys(67) -> gly in neurophysin II is associated with early onset autosomal dominant neurohypophyseal diabetes insipidus. Mol Genet Metab 72 (2001) 39-44
161. Baglioni S., Corona G., Maggi M., et al. Identification of a novel mutation in the arginine vasopressin-neurophysin II gene affecting the sixth intrachain disulfide bridge of the neurophysin II moiety. Eur J Endocrinol 151 (2004) 605-611
162. Davies J.H., Penney M., Abbes A.P., et al. Clinical features, diagnosis and molecular studies of familial central diabetes insipidus. Horm Res 64 (2005) 231-237
163. Santiprabhob J., Browning J., and Repaske D. A missense mutation encoding Cys73Phe in neurophysin II is associated with autosomal dominant neurohypophyseal diabetes insipidus. Mol Genet Metab 77 (2002) 112-118
164. Fujii H., Iida S., and Moriwaki K. Familial neurohypophyseal diabetes insipidus associated with a novel mutation in the vasopressin-neurophysin II gene. Int J Mol Med 5 (2000) 229-234
165. van den Akker E.L., de Groot M.R., Abbes A.P., et al. [Identification of a new mutation (CysII6Gly) in a family with neurogenic diabetes insipidus.]. Ned Tijdschr Geneeskd 144 (2000) 941-945
166. den Dunnen J.T., and Antonarakis S.E. Mutation nomenclature extensions and suggestions to describe complex mutations. A discussion. Hum Mutat 15 (2000) 7-12